JPMorgan Chase & Co. Lowers Envista (NYSE:NVST) Price Target to $19.00

Envista (NYSE:NVSTGet Free Report) had its price target cut by equities researchers at JPMorgan Chase & Co. from $20.00 to $19.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 2.90% from the stock’s current price.

NVST has been the topic of a number of other reports. Morgan Stanley cut their price target on Envista from $20.00 to $19.00 and set an “equal weight” rating on the stock in a research note on Thursday. Mizuho started coverage on Envista in a research note on Wednesday, December 4th. They set an “underperform” rating and a $20.00 price target on the stock. Wells Fargo & Company lifted their price target on Envista from $20.00 to $21.00 and gave the company an “equal weight” rating in a research note on Thursday, February 6th. Piper Sandler lifted their price objective on Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Envista in a research note on Thursday. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $20.38.

Check Out Our Latest Stock Report on Envista

Envista Stock Performance

NYSE:NVST opened at $18.47 on Thursday. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $3.18 billion, a PE ratio of -2.85, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33. Envista has a twelve month low of $15.15 and a twelve month high of $23.00. The stock’s 50-day simple moving average is $20.24 and its 200 day simple moving average is $19.68.

Envista (NYSE:NVSTGet Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. On average, analysts anticipate that Envista will post 1 EPS for the current fiscal year.

Hedge Funds Weigh In On Envista

Several institutional investors have recently added to or reduced their stakes in NVST. Huntington National Bank grew its holdings in Envista by 97.8% during the third quarter. Huntington National Bank now owns 1,919 shares of the company’s stock worth $38,000 after buying an additional 949 shares in the last quarter. Venturi Wealth Management LLC grew its holdings in Envista by 528.4% during the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock worth $38,000 after buying an additional 1,638 shares in the last quarter. GAMMA Investing LLC grew its holdings in Envista by 30.5% during the fourth quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock worth $44,000 after buying an additional 538 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Envista during the fourth quarter worth $53,000. Finally, Mitsubishi UFJ Trust & Banking Corp bought a new stake in Envista during the fourth quarter worth $86,000.

Envista Company Profile

(Get Free Report)

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.

Recommended Stories

Analyst Recommendations for Envista (NYSE:NVST)

Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.